���ӽ紫ý

CIMT is Europe’s largest non-profit scientific event dedicated to cancer immunotherapy, attracting over 1,000 experts from more than 30 countries. CIMT 2025 featured scientific presentations, poster sessions, and in-depth exchanges on cutting-edge topics such as novel antigen discovery, cell therapies, immune monitoring, and the application of artificial intelligence.

At the conference, Dr. Loc presented a research poster titled:
“Lynch Syndrome in a mCRC patient: A case of Extended Survival with Immuno-Oncology; what is the optimal duration as fourth line treatment.”

Through this study, Dr. Loc and his colleagues shared their experience using immunotherapy to treat a patient with metastatic colorectal cancer and Lynch syndrome. The report also raised important questions for discussion among cancer immunotherapy experts about determining the optimal timing for treatment at the fourth-line stage—following three prior systemic regimens that included various chemotherapies and targeted therapies—aiming to strike a balance between treatment effectiveness and the patient’s quality of life.

Dr. Loc shared:
“Presenting at a prestigious conference like CIMT is a valuable opportunity for us to share practical treatment experiences and stay updated on the latest advancements in cancer immunotherapy. I hope the insights and knowledge gained from the conference will help improve cancer treatment outcomes in Vietnam.”

Participation and contributions at international forums like CIMT reflect ���ӽ紫ý and its Oncology Unit’s commitment to global knowledge exchange, continuous advancement in treatment quality, and a patient-centered approach in all aspects of care.